<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>338</serviceExecutionTime><Drug id="79185"><DrugName>epoetin alfa follow-on biologic, Probiomed</DrugName><DrugNamesKey><Name id="42984604">Bioyetin</Name><Name id="42758552">epoetin alfa</Name></DrugNamesKey><DrugSynonyms><Name><Value>epoetin alfa</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>epoetin alfa follow-on biologic, Probiomed</Value></Name><Name><Value>Bioyetin</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1059298">Probiomed S.A. de C.V</CompanyOriginator><CompaniesPrimary><Company id="1059298">Probiomed S.A. de C.V</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1059298" type="Company"><TargetEntity id="4297801485" type="organizationId">Probiomed SA de CV</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="PTGT-03045" type="ciTarget"><TargetEntity id="92553377420563" type="siTarget">Erythropoietin</TargetEntity><TargetEntity id="245" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anemia - Mexico - Mar-2006</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="17">Anemia</Indication></IndicationsPrimary><ActionsPrimary><Action id="12162">Erythropoietin ligand</Action></ActionsPrimary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action></ActionsSecondary><Technologies><Technology id="647">Subcutaneous formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="74">Glycoprotein</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology><Technology id="961">Follow on biological product</Technology></Technologies><LastModificationDate>2012-07-25T10:25:59.000Z</LastModificationDate><ChangeDateLast>2016-06-15T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-20T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1059298"&gt;Probiomed&lt;/ulink&gt; has developed and launched Bioyetin, an injectable follow-on biologic version of recombinant human erythropoietin (rhEPO), presumed to be based on &lt;ulink linkType="Drug" linkID="6797"&gt;epoetin alfa&lt;/ulink&gt;, for the treatment of anemia in patients with secondary anemia due to chronic renal insufficiency, including patients on dialysis to reduce their transfusion needs, and in patients with HIV infection or malignancies. By March 2006, the product had been launched in Mexico [&lt;ulink linkType="Reference" linkID="1306708"&gt;1306708&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1059298">Probiomed S.A. de C.V</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-01T00:00:00.000Z</StatusDate><Source id="1306708" type="CORPORATE"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-03045"><Name>Erythropoietin ligand</Name><SwissprotNumbers><Swissprot>P01588</Swissprot><Swissprot>P07321</Swissprot><Swissprot>P07865</Swissprot><Swissprot>P29676</Swissprot><Swissprot>P33707</Swissprot><Swissprot>P33708</Swissprot><Swissprot>P33709</Swissprot><Swissprot>P48617</Swissprot><Swissprot>P49157</Swissprot><Swissprot>Q28513</Swissprot><Swissprot>Q867B1</Swissprot><Swissprot>Q9GKA2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ANALIZA Inc" id="1004873"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chung Shan Medical University" id="1031584"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Raygene Biotech International Inc" id="1138425"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novo Nordisk A/S" id="18614"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University Of Massachusetts" id="20615"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Louisville" id="21246"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Deutsches Krebsforschungszentrum" id="23844"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neose Technologies Inc" id="24203"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>